Different Oral Antithrombotic Therapy for the Treatment of Ventricular Thrombus: An Observational Study from 2010 to 2019

Table 4

The secondary outcomes of VT patients within 12 months’ follow-up (N (%)).

	NOACs (n = 77)	VKAs (n = 199)	Antiplatelet therapy (n = 187)	Total (n = 463)	value
Bleeding	1 (1.3)	12 (6.0)	12 (6.4)	25 (5.4)	0.216
Thromboembolism	0 (0)	1 (0.5)	1 (0.5)	2 (0.4)	1.000
All-cause death	0 (0)	5 (2.5)	2 (1.1)	7 (1.5)	0.392

Calculated by Fisher’s exact test. VT: ventricular thrombus; N: number of patients; NOACs: non-vitamin K antagonist oral anticoagulants; VKAs: vitamin K antagonists.